Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CRHBP | P24387 | 1/20 | 0.58 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | MYOC | Q99972 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5169625 | 0.88 | FFAR1 (0.69) | MEN1KMT2ASMN1; SMN2FFAR1KDM4E | |
| SCHEMBL5169615 | 0.88 | FFAR1 (0.69) | MEN1KMT2ASMN1; SMN2FFAR1KDM4E | |
| SCHEMBL10824904 | 0.87 | FFAR1 (0.58) | MEN1KMT2ASMN1; SMN2FFAR1KDM4E | |
| SCHEMBL13192698 | 0.86 | MAPT (0.69) | MEN1KMT2ASMN1; SMN2FFAR1MAPT | |
| SCHEMBL9367406 | 0.86 | KMT2A (0.77) | MEN1KMT2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL4367559 | 0.85 | MEN1 (0.65) | MEN1KMT2ASMN1; SMN2FFAR1MAPT | |
| SCHEMBL22225262 | 0.85 | FFAR1 (0.73) | MEN1KMT2AFFAR1KDM4EMAPT | |
| SCHEMBL14375415 | 0.85 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2FFAR1MAPT | |
| SCHEMBL9162294 | 0.84 | MTNR1B (0.77) | MEN1KMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL17326722 | 0.84 | CYP2C9 (0.60) | MEN1KMT2ASMN1; SMN2POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| EP-1539754-A4 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1325910-B1 | ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| EP-1692085-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | Chiron Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | CHIRON CORPORATION | 2005-11-24 | — | — | US | disclosed |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHIRON CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHEK1, CHEK2, RAD1 | MEN1 1441/4885KMT2A 2213/4885SMN1; SMN2 1651/4885 |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | FGFR3, FGFR1, FGFR2 | MEN1 319/4885KMT2A 2077/4885SMN1; SMN2 1216/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | MEN1 2588/4885KMT2A 2211/4885SMN1; SMN2 2956/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | MEN1 1691/4885KMT2A 953/4885SMN1; SMN2 976/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | MEN1 2178/4885KMT2A 2237/4885SMN1; SMN2 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.